+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID03214562

Study of Venetoclax With FLAG-IDA Chemotherapy in Patients With Newly Diagnosed or RelapsedRefractory Acute Myeloid Leukemia

Led by M.D. Anderson Cancer Center · Updated on 2026-11-02

116

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the best dose, side effects, and effectiveness of venetoclax combined with chemotherapy in patients with newly diagnosed or relapsedrefractory acute myeloid leukemia AML. This phase IbII trial aims to determine the safety and activity of this combination, including response rates and survival outcomes. The study also seeks to identify biomarkers that may predict venetoclaxs activity. Participants receive venetoclax orally along with a combination chemotherapy regimen called FLAG-IDA, which includes fludarabine, cytarabine, filgrastim or pegfilgrastim, and idarubicin. Treatment is given in three phases induction therapy for up to 2 cycles, consolidation therapy for up to 6 cycles, and maintenance therapy for up to 1 year, each repeated every 28 days if there is no disease progression or unacceptable toxicity. During the study, patients undergo regular assessments including blood tests, response evaluations using standardized criteria, and monitoring of side effects. Researchers measure outcomes such as overall response rate, duration of response, event-free survival, overall survival, drug exposure levels, and adverse events over up to 6 years. After treatment, patients have follow-up visits within 30 days to monitor safety and response.

CONDITIONS

Brief Title

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

Research Team

D

DiNardo, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here